Trial reportPloS one2014
Field efficacy of Vectobac GR as a mosquito larvicide for the control of anopheline and culicine mosquitoes in natural habitats in Benin, West Africa.
Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Larviciding to prevent malaria transmission.The Cochrane database of systematic reviews · 2019Pooled it
- Review
- Lessons learned exploiting a multi-year large-scale data set derived from operational quality assessment of mosquito larval treatments in rain catch basins.Pest management science · 2025Article
- Influence of larval growth and habitat shading on retreatment frequencies of biolarvicides against malaria vectors.Scientific reports · 2024Article
- Evaluation of different deployment strategies for larviciding to control malaria: a simulation study.Malaria journal · 2021Article
- Community factors affecting participation in larval source management for malaria control in Chikwawa District, Southern Malawi.Malaria journal · 2020Article
- Susceptibility of mosquito vectors of the city of Praia, Cabo Verde, to Temephos and Bacillus thuringiensis var israelensis.PloS one · 2020Article
- Bacterial larvicides used for malaria vector control in sub-Saharan Africa: review of their effectiveness and operational feasibility.Parasites & vectors · 2019Review
- Impact of sunlight exposure on the residual efficacy of biolarvicides Bacillus thuringiensis israelensis and Bacillus sphaericus against the main malaria vector, Anopheles gambiae.Malaria journal · 2019Article
- Efficacy and persistence of long-lasting microbial larvicides against malaria vectors in western Kenya highlands.Parasites & vectors · 2018Article
- Field testing & evaluation of the efficacy & duration of effectiveness of a biolarvicide, BactivecThe Indian journal of medical research · 2018Article
- Mapping insecticide resistance in Anopheles gambiae (s.l.) from Côte d'Ivoire.Parasites & vectors · 2018Article
- Stability assessment of hydro dispersive nanometric permethrin and its biosafety study towards the beneficial bacterial isolate from paddy rhizome.Environmental science and pollution research international · 2016Article
- Effects of larvicidal and larval nutritional stresses on Anopheles gambiae development, survival and competence for Plasmodium falciparum.Parasites & vectors · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionThe efficacy of Vectobac GR (potency 200 ITU/mg), a new formulation of bacterial larvicide Bacillus thuringiensis var. israelensis Strain AM65-52, was evaluated against Anopheles gambiae and Culex quinquefasciatus in simulated field and natural habitats in Benin.
methodsIn simulated field conditions, Vectobac GR formulation was tested at 3 dosages (0.6, 0.9, 1.2 g granules/m² against An. gambiae and 1, 1.5, 2 g granules/m² against Cx. quinquefasciatus) according to manufacturer's product label recommendations. The dosage giving optimum efficacy under simulated field conditions were evaluated in the field. The efficacy of Vectobac GR in terms of emergence inhibition in simulated field conditions and of reduction of larval and pupal densities in rice fields and urban cesspits was measured following WHO guidelines for testing and evaluation of mosquito larvicides.
resultsVectobac GR caused emergence inhibition of ≥80% until 21 [20]-[22] days for An. gambiae at 1.2 g/m² dose and 28 [27-29] days for Cx. quinquefasciatus at 2 g/m² in simulated field habitats. The efficacy of Vectobac GR in natural habitats was for 2 to 3 days against larvae and up to 10 days against pupae.
conclusionsTreatment with Vectobac GR caused complete control of immature mosquito within 2-3 days but did not show prolonged residual action. Larviciding can be an option for malaria and filariasis vector control particularly in managing pyrethroid-resistance in African malaria vectors. Since use of larvicides among several African countries is being emphasized through Economic Community of West Africa States, their epidemiological impact should be carefully investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.